Codexis Inc signs technology license agreement with GlaxoSmithKline

Codexis sign technology license agreement with GlaxoSmithKline

10:18 AM, 15th July 2014
Codexis Inc signs technology license agreement with GlaxoSmithKline
John Nicols, President and CEO, Codexis.

REDWOOD CITY, US: Codexis Inc, a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announced the signing of a platform technology license agreement with GlaxoSmithKline (GSK).

Under the terms of the agreement, Codexis granted GSK a license to use Codexis’ proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. The license allows GSK to use Codexis’ platform technology to develop novel enzymes for use in the manufacture of GSK’s pharmaceutical and health care products. GSK may also use the licensed technology to develop new therapeutic, diagnostic and prophylactic products in the human health field. Upon completion of technology transfer, GSK will have Codexis’ state-of-the-art CodeEvolver protein engineering platform installed at its Upper Merion, Pennsylvania research and development site.

The agreement marks the first time that Codexis has licensed its protein engineering platform technology to any party in the healthcare field, and reinforces both companies’ belief that biocatalysts, engineered by Codexis’ CodeEvolver technology, may increasingly be deployed to reduce the cost and increase the efficiency of pharmaceutical manufacturing. The use of biocatalysts to manufacture pharmaceuticals has the potential to reduce the number of manufacturing steps, reduce the use of hazardous chemicals and the production of toxic waste, and reduce the energy intensity of the process.

“We are very pleased that GSK has selected our CodeEvolver platform technology to support innovation and reduce costs in its manufacturing and product development organizations. We look forward to replicating this new technology licensing model with other potential partners and expanding the network of innovative companies that may select our CodeEvolver technology to accelerate their in-house protein engineering capabilities,” said John Nicols, President and CEO, Codexis.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Evonik forms fumed silica, ultra-pure silicon tetrachloride JV in China

ESSEN, GERMANY: Evonik Industries and Jiangsu Zhongneng Polysilicon Technology Development Co Ltd, a wholly owned subsidiary of GCL-Poly Energy Holdin ...

Read more
Towards using carbon components as electrodes

HOUSTON, US: Lithium-ion batteries could benefit from a theoretical model created at Rice University and Lawrence Livermore National Laboratory that p ...

Read more
Linde opens small-series hydrogen fuelling stations in Vienna, Austria

MUNICH, GERMANY/VIENNA, AUSTRIA: The Linde Group officially opened the world’s first small-series production facility for hydrogen fuelling stat ...

Read more
Hexpol to acquire US rubber compounder, Kardoes

EUPEN, BELGIUM: Hexpol has signed an agreement to acquire the business of Kardoes Rubber Co. a well-known Rubber Compounder in the US market. Kardoes ...

Read more
Study of mechanics of photosynthesis promises efficient energy storage system

ANN ARBOR, US: Biophysics researchers at the University of Michigan have used short pulses of light to peer into the mechanics of photosynthesis and i ...

Read more
EuroChem starts phosphate ore production at Kazakhstan

MOSCOW, RUSSIA/KARATAU, KAZAKHSTAN: EuroChem, a top ten fertilizer company globally, announced the launch of phosphate ore production at the Kok-Jon p ...

Read more